Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Bristol Myers Squibb

Main (gene editing) focus: Next-generation cellular therapies

Company stage: Commercial

Diseases (gene editing): Acute myeloid leukaemia (AML), multiple myeloma (MM), other haematological and solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:BMY)

Location: New York City, New York, USA



Gene editing partnerships: Century Therapeutics

Bristol Myers Squibb (BMS) is a big pharma company developing drugs within many different disease areas. The company is engaged in the gene-editing space through its collaboration with Century Therapeutics, which is an early stage company developing gene-edited iPSC-derived cellular therapies. Together, the two companies will develop programmes with the intent to treat acute myeloid leukaemia and multiple myeloma.


HashtagBristol Myers Squibb

Company: Bristol Myers Squibb
Search CRISPR Medicine